Common (5-15% of users): Mild injection site reactions, minor digestive changes Uncommon (1-5%): Sleep changes, temporary fatigue, mild headache Rare (under 1%): Dizziness, flushing, mood changes Very Rare: Serious adverse effects rarely reported in community use Theoretical Concerns BPC-157s ability to stimulate angiogenesis (blood vessel formation) raises theoretical questions about its use in individuals with active cancer or high cancer risk
EDCs could plausibly drive prostate carcinogenesis by directly or indirectly affecting components of key survival pathways, resulting in the enhancement of cell-cycle progression, inhibition of apoptosis and stimulation of metastatic capacity
The FDA does not approve compounded medications for safety, quality, or manufacturing
Although it is unknown whether it is excreted in human milk, caution is advised
I placed it in the category of cautious, hypothesis-driven experimentation
Can I take Apixaban and Sertraline together